Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

Table 1 Baseline characteristics

	Vemurafenib (N = 46)
Age, y, median (range)	42 (19–69)
Male, n (%)	21 (46)
ECOG performance status, n (%)
0	30 (65)
1	16 (35)
Serum LDH level, n (%)
Normal	27 (59)
Elevated	19 (41)
Histologic subtype, n (%)
Acral lentiginous	1 (2)
Nodular	7 (15)
Pigmented nevus	1 (2)
Superficial spreading	14 (30)
Unknown	23 (50)
Median time since diagnosis of metastatic disease (range), months	4.5 (0–31.0)
Disease stage, n (%)
Unresectable stage IIIC	3 (7)
Stage IV	43 (94)
M1a^a	9 (21)
M1b^a	8 (19)
M1c^a	26 (61)
Prior treatment for metastatic disease, n (%)	31 (67)
Number of prior therapies for metastatic disease, n (%)
0	15 (33)
1	21 (46)
2	6 (13.0)
≥ 3	3 (7)
Unknown	1 (2)
Previous CTLA-4 or PD-1/PD-L1 inhibitor, n (%)	0 (0)

ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase; CTLA-4 cytotoxic T-lymphocyte-associated protein 4; PD-1 programmed death 1; PD-L1 programmed death ligand 1
^aDenominator is the number of patients with stage IV disease (n = 43)

ISSN: 1471-2407